

# Volta Finance Ltd

## Monthly Report – March 2017



Data as at 31 March 2017

Gross Asset Value	€357.7m
Estimated liabilities	€46.6m
Estimated NAV	€311.1m
Estimated NAV per share	<b>€8.51</b>
Outstanding Shares	36.5m
Share Price (Euronext)	€7.25
Share Price (LSE)	€7.45
Tickers	VTA.NA VTA.LN
ISIN	GG00B1GHHH78

### Fund Facts

Launch Date	Dec-2006
Fund Domicile	Guernsey
Listing and Trading	AEX LSE
Type of Fund	Closed-ended
Dividend	Quarterly
Trailing 12m Div. Yield <sup>3</sup>	8.7%
Base currency	EUR
Assets types	Corporate Credit and ABS

### Background and Investment Objective

AXA Investment Managers Paris ("AXA IM") has been the Investment Manager of Volta Finance Limited ("Volta") since inception. Volta's investment objectives are to preserve capital across the credit cycle and to provide a stable stream of income to its Shareholders through dividends. For this purpose, Volta pursues a multi-asset investment strategy on deals, vehicles and arrangements that provide leveraged exposure to target Underlying Assets (including corporate credit, residential and commercial mortgages, auto and student loans, credit card and lease receivables).

### Fund Performance

<b>+11.7%</b>	<b>27.8%</b>
Annualised since inception <sup>1</sup>	Annualised over 5 years <sup>1</sup>
<b>0.9%</b>	<b>€311.1m</b>
1 month <sup>2</sup>	Estimated NAV as of March 17


Returns <sup>2</sup>	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2017	1.3%	0.9%	0.9%	-	-	-	-	-	-	-	-	-	3.2%
2016	-4.0%	-2.9%	4.1%	2.0%	1.3%	-0.9%	5.5%	2.8%	1.4%	2.0%	2.7%	1.4%	15.2%
2015	3.7%	1.3%	3.1%	1.7%	1.6%	-0.7%	0.1%	-0.6%	-1.7%	0.1%	1.1%	0.1%	10.0%
2014	2.7%	-1.6%	0.8%	0.7%	1.5%	0.7%	1.3%	1.3%	2.4%	0.4%	1.7%	0.3%	12.4%
2013	3.6%	1.5%	2.5%	0.1%	4.1%	-0.7%	3.1%	2.0%	0.7%	2.4%	2.9%	1.3%	25.3%

<sup>1</sup> Share (VTA.NA) performance (annualised figures with dividends re-invested). Source: Bloomberg (TRA function)

<sup>2</sup> Performance of published Estimated NAV (including dividend payments)


<sup>3</sup> Calculated as the most recent annual dividend payments versus the month-end share price (VTA.NA)

### Historical Performance



Source: Bloomberg (TRA function) as of March 2017

### Asset Breakdown



Source: AXA IM, as of March 2017

### Monthly Commentary

In March, Volta's Estimated NAV\* performance was +0.9%, in line with a positive performance in most credit and equity markets.

During the month, Volta purchased three assets (two USD CLO debt positions, one new USD CLO equity position) and the "CMV" announced in the January monthly report was partly drawn down for an aggregate equivalent of €13.4m. On average, and based on standard market assumptions, the purchases and the CMV drawdown have an average expected yield close to 10.7%. In March, three USD CLO debt were sold or called for an aggregate equivalent of €10.8m. On average, and based on standard market assumptions, the average expected yield of these three assets was close to 5.5%.

At the end of March 2017, Volta's Estimated NAV\* was €311.1m or €8.51 per share after a dividend of €15 cents per share was paid. The GAV stood at €357.7m.

In March, mark-to-market variations\*\* of Volta's asset classes were: +0.7% for Synthetic Corporate Credit deals; +1.8% for CLO Equity tranches; +1.5% for CLO Debt tranches, -10.9% for Cash Corporate Credit deals; and +0.2% for ABS.

# Volta Finance Ltd

## Monthly Report – March 2017

Cash corporate credit is a relatively small component of Volta (2.4% at the end of March) and the negative performance was due to the final payment of a German SME CDO (purchased by Volta in 2006) that depended on the assessment, by two independent experts, of the value of a pool of defaulted SME loans. By nature, this kind of final cash flow is always difficult to estimate. In recent years this asset has produced material cash flows well in excess of expectations but this last cash flow was below the carrying valuation. The impact was -0.4% to the monthly performance of Volta.

During March, Volta generated the equivalent of €0.7m in interest and coupons net of repo costs (non-euro amounts translated into euro using end-of-month cross currency rates). This brings the total cash amount generated during the last six months in terms of interest and coupons to €16.3m. Cash holdings or cash equivalent instruments at the end of March totaled €28.6m.

The current level of cash is higher than usual but reflects our view that credit markets are now quite fully valued and better opportunities will arise in due course. Typically we expect to be able to deploy more capital in CLO Equity tranches and in Bank Balance Sheet transactions. We expect to utilize CLO warehouse exposure as a way to access CLO equity positions with better economics.

Volta's currency exposure was relatively stable during March and the exposure to the US Dollar at month end was circa 24%.

A modest exposure continues to be maintained to duration, which was accretive to returns during March. Volta ended the month with a positive 0.3 years of duration via the overlay. In addition, a short position via options was initiated on the S&P500 during March given the growing uncertainty around the Trump administration. This S&P500 position is being utilized as a proxy credit hedge and represents 2.5% of Volta's NAV. These hedges are aimed at seeking to dampen downside volatility arising from shorter-term mark to market developments that may arise. Ultimately, the returns of Volta continue to be predominantly driven by the performance and the strong cash flows from the structured finance assets held but we believe that these hedges will contribute to a better short-term volatility profile.

*\* It should be noted that approximately 10.4% of Volta's GAV comprises investments in funds for which the relevant NAVs as at the month-end date are normally available only after Volta's NAV has already been published. Volta's policy is to publish its own NAV on as timely a basis as possible in order to provide shareholders with Volta's appropriately up-to-date NAV information. Consequently, such investments in funds are valued using the most recently available NAV for each fund. The most recently available fund NAV was as at: 30 September 2016 for 0.9% of Volta's GAV and as at 28 February 2017 for 9.5% of Volta's GAV.*

*\*\* "Mark-to-market variation" is calculated as the Dietz-performance of the assets in each bucket, taking into account the Mark-to-Market of the assets at month-end, payments received from the assets over the period, and ignoring changes in cross currency rates. Nevertheless, some residual currency effects could impact the aggregate value of the portfolio when aggregating each bucket.*

### Portfolio Composition by Asset Type


Market Value (€m)		Breakdown of Gross Asset Value (% GAV)	
CLO	256.5	USD CLO Equity	12.9%
		USD CLO Debt	42.3%
		EUR CLO Equity	12.2%
		EUR CLO Debt	4.2%
		CLO Warehouse	0.0%
Synthetic Corporate Credit	49.1	Synthetic Corporate Credit E	0.0%
		Bank Balance Sheet Transar	13.7%
Cash Corporate Credit	8.5	Cash Corporate Credit Equity	2.4%
		Cash Corporate Credit Debt	0.0%
ABS	15.0	Mortgage Residual Positions	1.8%
		ABS Debt	2.4%
Cash or equivalent	28.6	Cash or equivalent	8.0%
<b>GAV</b>	<b>357.7</b>		
Liability	(42.3)	Debt from Repurchase Agree	(11.8)%
Fees due	(4.3)	Fees due to Investment Man.	(1.2)%
<b>Estimated NAV</b>	<b>311.1</b>	<b>Per Share</b>	<b>8.51</b>

Source: AXA IM, as of March 2017

### Top 10 Underlying Exposures


Issuer	%	Bloomberg Industry Group
First Data	1.05%	Software
Altice Financing	0.81%	Telecommunications
Ineos Group	0.66%	Chemicals
Ziggo Secured Finance	0.63%	Telecommunications
TransDigm	0.62%	Aerospace/Defense

Source: Intex, Bloomberg, AXA IM Paris as of March 2017 – unaudited figures - not accounting for unsettled trades - Figures expressed in % of the Estimated NAV



Source: AXA IM, as of March 2017 (% of NAV for ccy / % of GAV for geography)

### Last Eighteen Months Performance Attribution



Source: AXA IM, as of March 2017

Issuer	%	Bloomberg Industry Group
Community Health Systems	0.60%	Healthcare
Energy Future	0.56%	Energy
Valeant Pharmaceuticals	0.46%	Pharmaceuticals
Kindred Healthcare	0.45%	Healthcare
Calpine	0.42%	Utilities

# Volta Finance Ltd

## Monthly Report – March 2017

### Important Information

This monthly report is distributed and published by AXA Investment Managers Paris ("AXA IM"), in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU, the "AIFM Directive") of Volta Finance Limited (the "Company") whose portfolio is managed by AXA IM. This monthly report is intended only for the person to whom it has been delivered. By obtaining access to and reviewing this monthly report, you acknowledge and agree to be bound by the following: No part of this document may be reproduced in any manner without the prior written permission of AXA IM. This monthly report does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company whose portfolio is managed by AXA IM, or securities of any other entity (together, the "Securities"). The Securities described in this monthly report may not be eligible for sale in some states or countries and may not be suitable for all types of investors. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Securities in the Company may not be offered or sold directly or indirectly into the United States or to U.S. Persons. Nor shall this monthly report or any part of it nor the fact of its distribution or publication (on the Company's website or otherwise) form the basis of, or be relied on in connection with, any contract or investment decision in relation to the Securities. This monthly report does not constitute a recommendation to buy, sell or hold the Securities. The information contained herein is for information purposes only, does not purport to contain all the information that may be required to evaluate the Company or any other entity or their respective financial positions. This monthly report speaks only as of its date and neither AXA IM nor the Company is under any obligation to update the information contained herein. Certain information and estimates contained herein are originated by or derived from third parties and the accuracy and completeness of such information and estimates has not been verified. It should also be noted that the financial information contained herein has not been audited. No representation or warranty whatsoever, whether express or implied, is given by or on behalf of AXA IM, the Company, their affiliates, or their respective directors, officers or employees or any other person as to (a) the accuracy or completeness of the information or (b) the opinions contained in this monthly report. None of AXA IM, the Company, any of their affiliates, or their respective directors, officers or employees or any other person accepts any liability whatsoever for any such information or opinions. Nothing contained herein shall be relied upon as a promise or representation whether as to past or future performance of the Company, any other entity, any Securities or any asset class in the Company's portfolio. The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review, the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of the Company, as implemented by AXA IM. The historical success or AXA IM's belief in the future success, of any of these trades or strategies is not indicative of, and has no bearing on, future results. No statement in this monthly report is intended to be nor may be construed as a profit forecast and there can be no assurance that the assumptions described herein, the returns and targets (including without limitation target portfolio composition) indicated herein will be achieved. The views and opinions expressed herein include forward-looking statements which may or may not be accurate. Forward-looking statements can be identified by words like "believe", "expect", "anticipate", or similar expressions. You should not place undue reliance on forward-looking statements, which are current as of the date of this report. AXA IM disclaims any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. The valuation of financial assets can vary significantly from the prices that the AXA IM could obtain if it sought to liquidate the positions on behalf of the Company due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such. They follow the valuation policy of the Company as adapted from time to time in the best interests of the shareholders, taking into account the conditions of financial markets at that time. Volta qualifies as an alternative investment fund within the meaning of the AIFM Directive and is notified as such under the license held by AXA IM with the Autorité des Marchés Financiers (the "AMF") in France.

Editor: AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6, Place de la Pyramide 92908 Paris – La Défense cedex – France, registered with the Nanterre Trade and Companies Register under number 353 534 506, a Portfolio Management Company, holder of AMF Approval no. GP 92-08, issued on 7 April 1992.

### Contact:

**For the Investment Manager**  
AXA Investment Managers Paris  
Serge Demay  
Serge.demay@axa-im.com  
+33 (0) 1 44 45 84 47

**Company Secretary and Portfolio  
Administrator**  
Sanne Group (Guernsey) Limited  
voltafinance@sannegroup.com  
+44 (0) 1481 739810